2-氯乙酰氨基-2',5-二氯二苯甲酮 | 14405-03-9

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯乙酰氨基-2',5-二氯二苯甲酮
• 中文别名: 2`-(2-氯苯甲酰基)-2,4`-二氯乙酰苯胺；2-氯乙酰氨基-2’,5-二氯二苯甲酮；2-氯-N-[4-氯-2-(2-氯苯甲酰基)苯基]乙酰胺
• 英文名称: 2-(chloroacetamido)-5,2'-dichlorobenzophenone
• 英文别名: 2,4'-Dichloro-2'-o-chlorobenzoylacetanilide；2-chloro-N-[4-chloro-2-(2-chlorobenzoyl)phenyl]acetamide
• CAS: 14405-03-9
• 化学式: C₁₅H₁₀Cl₃NO₂
• mdl: MFCD00000927
• 分子量: 342.609
• InChiKey: VCBRYYAFVLDIHK-UHFFFAOYSA-N

物化性质

• 熔点：
  159-161 °C(lit.)
• 沸点：
  565.0±50.0 °C(Predicted)
• 密度：
  1.452±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、甲醇（微溶、加热、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.066
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• WGK Germany：
  3
• 海关编码：
  2924299090
• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P501,P273,P260,P270,P264,P280,P391,P314,P337+P313,P305+P351+P338,P301+P312+P330
• 危险品运输编号：
  3077
• 危险性描述：
  H302,H319,H372,H410
• 储存条件：
  请将药品贮存于阴凉处，并保持容器密闭，在干燥、通风良好的地方存放。

SDS

Name:	2-Chloro-N-[4-chloro-2-(2-chlorobenzoyl)phenyl]acetamide 97% Material Safety Data Sheet
Synonym:
CAS:	14405-03-9

Section 1 - Chemical Product MSDS Name:2-Chloro-N-[4-chloro-2-(2-chlorobenzoyl)phenyl]acetamide 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
14405-03-9	2-Chloro-N-[4-chloro-2-(2-chlorobenzoy	97%	238-376-5

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 14405-03-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 161 - 163 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H10Cl3NO2
Molecular Weight: 343

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 14405-03-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Chloro-N-[4-chloro-2-(2-chlorobenzoyl)phenyl]acetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 14405-03-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 14405-03-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 14405-03-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯乙酰氨基-2',5-二氯二苯甲酮 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.5h， 生成 7-氯-5-(2-氯苯基)-1,3-二氢-3H-1,4-苯并二氮杂卓-2-酮
  参考文献：
  名称：

  咪唑啉丁-4-酮的合成及其转化为1,4-苯并二氮杂-2-酮

  摘要：

  α-卤代乙酰苯胺Ia-e与乙醇中的六胺反应，生成双咪唑啉丁-4-酮衍生物IIa-e，该衍生物在酸性介质中水解成相应的单咪唑啉丁-4-酮Ⅲa-e。在不同条件下，在多种试剂的存在下，化合物IIa-d被转化为1,4-苯并二氮杂-2-酮。产率在50％至100％之间。

  DOI：

  10.1002/jhet.5570180523
• 作为产物：
  描述：

  对氯苯胺 在 zinc(II) chloride 作用下， 以 甲苯 为溶剂， 反应 0.04h， 生成 2-氯乙酰氨基-2',5-二氯二苯甲酮
  参考文献：
  名称：

  含氮芥子基部分作为潜在中枢神经系统抗肿瘤剂的氨基二苯甲酮衍生物的设计，合成和评估

  摘要：

  合成了一系列含有氮芥子部分（5a - f）的新型取代氨基二苯甲酮衍生物，并根据其IR，1 H NMR，13 C NMR，CHN和质谱数据进行了表征。当评估4-（4-硝基苄基）吡啶烷基化化学活性时，所有化合物均证明是活性烷基化剂。通过计算，在线软件和QikProp 3.2对所有合成的化合物进行中枢神经系统（CNS）活动所需的理化参数测定。日志P值和分析的其他计算机模拟ADME理化指标位于良好BBB渗透所需的范围之间。对人癌细胞系的体外抗增殖活性。研究了549（肺），COLO 205（结肠），U 87（胶质母细胞瘤）和IMR-32（神经母细胞瘤）。大多数测试化合物显示出有效的抗肿瘤活性，尤其是化合物（5f）显示出最高的抗CNS癌细胞活性，与苯丁酸氮芥和多西紫杉醇相当。初步的构效关系（SAR）表明，5-氯氨基二苯甲酮-芥末系列（5a-c）比5-硝基氨基二苯甲酮-芥末系列（5d-f）表现出更好的抗肿瘤活性。

  DOI：

  10.1007/s00044-013-0582-8

文献信息

• Cyanoalkylamino-amido benzophenones
  申请人：Cassella Farbwerke Mainkur Akt

  公开号：US03950383A1

  公开（公告）日：1976-04-13

  The present invention relates to pharmacologically valuable new benzophenone derivatives having a pronounced sedative action on the central nervous system and some of which also possess muscle-relaxing and aggression-inhibiting properties. These new derivatives have the structural formula ##SPC1## And their addition salts, in which R.sub.1 and R.sub.2 are substituents selected from the group consisting of hydrogen, alkyl having 1-5 carbon atoms, alkenyl having 2 to 4 carbon atoms, alkinyl having 2 to 4 carbon atoms or .beta.-bromoallyl (--CH.sub.2 --CBr = CH.sub.2) ; R.sub.3 is --CN; n is an integer selected from 1 and 2; and m is an integer selected from 1, 2 and 3, wherein the rings A and B may be substituted, ring A being substituted preferably with a halogen such as chlorine or with nitro, trifluoromethyl, methyl, methoxy or methylmercapto, preferably in the 5 position, and ring B being preferably substituted in the 2' position with chlorine or fluorine. The radical R.sub.1 preferably signify hydrogen or a methyl, ethyl or propargyl group, the radicals for R.sub.2 preferably signify hydrogen or a methyl, allyl or an n-butyl group. C compounds represented by the above structural formula may be produced by reacting a compound represented by the formula ##SPC2## With a compound having the formula Y -- C.sub.m H.sub.2m -- R.sub.3, one of X and Y signifying the substituent R.sub.2 -- NH -- and the other signifying a halogen atom, preferably a bromine or chlorine atom, so as to form the above specified benzophenone derivative with the elimination of H -- Hal, R.sub.1, R.sub.2, R.sub.3, n and m being as defined above, and the rings A and B being optionally substituted as discussed above. The hydrogen halide which is eliminated is advantageously bound by the addition of an acid-binding agent, as for example, a molar excess of the amine used in the reaction or, for example, triethylamine, dimethylaniline, potassium or sodium carbonate or sodium bicarbonate. The reaction is carried out in a suitable solvent, preferably at an elevated temperature, typically the reflux temperature of the solvent used.

  本发明涉及具有明显镇静作用于中枢神经系统的药理学上有价值的新苯酮衍生物，其中一些还具有肌肉松弛和抑制攻击性质。这些新衍生物具有结构式##SPC1##及其加合盐，其中R.sub.1和R.sub.2是从氢，具有1-5个碳原子的烷基，具有2到4个碳原子的烯基，具有2到4个碳原子的炔基或.beta.-溴丙烯基（--CH.sub.2 --CBr = CH.sub.2）中选择的取代基；R.sub.3是--CN；n是选自1和2的整数；m是选自1、2和3的整数，其中环A和环B可以被取代，环A取代物最好是氯或硝基，三氟甲基，甲基，甲氧基或甲硫基，最好在5位，环B最好在2'位取代氯或氟。基团R.sub.1最好表示氢或甲基，乙基或丙炔基，基团R.sub.2最好表示氢或甲基，烯丙基或正丁基。上述结构式所代表的C化合物可以通过将由下式表示的化合物与具有下式Y -- C.sub.m H.sub.2m -- R.sub.3的化合物反应来制备，其中X和Y中的一个表示取代基R.sub.2 -- NH --，另一个表示卤原子，最好是溴或氯原子，以形成上述指定的苯酮衍生物，消除H -- Hal，R.sub.1，R.sub.2，R.sub.3，n和m如上所定义，环A和环B如上所述可能被取代。消除的氢卤酸可通过添加酸结合剂结合，例如，在反应中使用的胺的过量摩尔量，例如三乙胺，二甲苯胺，碳酸钾或碳酸钠。反应在适当的溶剂中进行，最好在升高的温度下进行，通常是所用溶剂的回流温度。
• Benzoxazinone-derived compounds, their preparation and use as medicaments
  申请人：——

  公开号：US20040058920A1

  公开（公告）日：2004-03-25

  The present invention relates to Benzoxazinone-derived compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.

  本发明涉及一般式（I）的苯并噁唑酮衍生物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类或动物的药物的用途。
• [EN] ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY<br/>[FR] COMBINAISON DE SUBSTANCES ACTIVES COMPORTANT UN COMPOSE A AFFINITE DE RECEPTEUR NPY ET UN COMPOSE A AFFINITE DE RECEPTEUR 5-HT6
  申请人：ESTEVE LABOR DR

  公开号：WO2005014000A1

  公开（公告）日：2005-02-17

  The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种具有神经肽Y受体亲和力的化合物和至少一种具有5-HT6受体亲和力的化合物，以及包含所述活性物质组合的药物和利用该活性物质组合制造药物的用途。
• 一种劳拉西泮中间体的制备方法
  申请人：北京益民药业有限公司

  公开号：CN112028844A

  公开（公告）日：2020-12-04

  本发明提供了一种劳拉西泮中间体的制备方法，所述劳拉西泮中间体为7‑氯‑5‑(2‑氯苯基)‑1,3‑二氢‑2H‑1,4‑苯并二氮杂卓‑2‑酮‑4‑氧化物，所述制备方法包括以下步骤：(1)2‑氨基‑2’,5‑二氯二苯甲酮与氯乙酰氯进行酰化反应，制得2‑氯乙酰氨基‑2’,5‑二氯二苯甲酮；(2)2‑氯乙酰氨基‑2’,5‑二氯二苯甲酮与乌洛托品和醋酸铵反应，制得7‑氯‑5‑(2‑氯苯基)‑1,3‑二氢‑2H‑1,4‑苯并二氮杂卓‑2‑酮；和(3)7‑氯‑5‑(2‑氯苯基)‑1,3‑二氢‑2H‑1,4‑苯并二氮杂卓‑2‑酮与双氧水进行氧化反应，制得7‑氯‑5‑(2‑氯苯基)‑1,3‑二氢‑2H‑1,4‑苯并二氮杂卓‑2‑酮‑4‑氧化物。本发明的制备方法简便，反应条件温和，收率高，产品质量好，成本低。
• Axial chirality and affinity at the GABAA receptor of triazolobenzodiazepines
  作者：Ryoko Tanaka、Kosho Makino、Hidetsugu Tabata、Tetsuta Oshitari、Hideaki Natsugari、Hideyo Takahashi

  DOI：10.1016/j.bmc.2022.116758

  日期：2022.6

  absolute configurations were determined on the basis of CD spectra in comparison with those of stereochemically defined 9-methyl-1,4-benzodiazepin-2-ones. Examination of the affinity at the human GABAA receptors revealed that each (a1R, a2S) isomer of 1d and 1f possessed higher activity than its antipode (a1S, a2R) isomer. It was also found that 1a, which behaves achirally due to the rapid conformational

  制备了C 1 和C 10 位甲基和C 2' 氯基取代的三唑并苯二氮卓类化合物，并研究了它们的理化性质。1,10-二取代的三唑并苯二氮卓类的阻转异构体1d和1f被分离为(a 1 R , a 2 S ) 和(a 1 S , a 2 R ) 异构体。它们的绝对构型是根据 CD 光谱与立体化学定义的 9-methyl-1,4-benzodiazepin-2-ones 相比确定的。检查人 GABA A的亲和力受体表明，1d和1f的每个（a 1 R，a 2 S）异构体都比其对映体（a 1 S，a 2 R ）异构体具有更高的活性。还发现由于快速构象变化而表现出非手性的1a具有最高的 GABA A亲和力，与三唑仑相同。考虑到1d和1f的每个eutomer都是(a 1 R , a 2 S )，1a在GABA A结合位点的构象受体预计为（a 1 R，a 2 S）。